3-Amino-4-naphthalen-1-ylbutan-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-Amino-4-naphthalen-1-ylbutan-2-one
• 英文别名: 3-amino-4-naphthalen-1-ylbutan-2-one
• 化学式: C₁₄H₁₅NO
• 分子量: 213.27
• InChiKey: SOCQGYBXMSTAFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS<br/>[FR] PEPTIDOMIMÉTIQUES POUR LE TRAITEMENT D'INFECTIONS PAR CORONAVIRUS ET PICORNAVIRUS
  申请人：UNIV EMORY

  公开号：WO2020247665A1

  公开（公告）日：2020-12-10

  Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or Hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV- 2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

  用于预防、治疗或治愈人类主体或其他动物宿主中的冠状病毒、小RNA病毒和/或肝炎病毒感染的化合物、组合物和方法。可治疗的特定病毒包括肠病毒。在一个实施例中，这些化合物可用于治疗严重急性呼吸综合征病毒感染，如人类冠状病毒229E、SARS、MERS、SARS-CoV-1（OC43）和SARS-CoV-2。在另一个实施例中，这些方法用于治疗患有两种或更多这些病毒的患者，或一种或多种这些病毒与诺如病毒的组合。
• IMPROVED PEPTIDE PHARMACEUTICALS
  申请人：Eumederis Pharmaceuticals, Inc.

  公开号：EP3444281A1

  公开（公告）日：2019-02-20

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可改善基于肽和蛋白质的疗法的药物特性。
• Peptide pharmaceuticals
  申请人：Nestor John J.

  公开号：US10010617B2

  公开（公告）日：2018-07-03

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可改善基于肽和蛋白质的疗法的药物特性。
• IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
  申请人：Mederis Diabetes, LLC

  公开号：EP2710031B9

  公开（公告）日：2018-02-28
• NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM
  申请人：Chatenet David

  公开号：US20140113872A1

  公开（公告）日：2014-04-24

  Novel urotensin ll receptor (UT) agonists and antagonists are described herein. More specifically, novel derivatives of urotensin ll-related peptide (URP) are described herein.